Decrease in [3H]-serotonin binding in rat brain produced by the repeated administration of either monoamine oxidase inhibitors or centrally acting serotonin agonists

D. D. Savage, J. Mendels, A. Frazer

Research output: Contribution to journalArticlepeer-review

44 Scopus citations

Abstract

The effect of repeated administration of monoamine oxidase inhibitors or serotonin agonists on [3H]-serotonin binding and serotonin concentrations in rat cerebral cortex was examined. Five days of clorgyline administration, which alone caused a significant reduction in [3H]-serotonin binding, was unable to do this in animals pretreated with drugs that deplete brain serotonin. Pretreatment of rats with alpha-methyl-paratyrosine did not block the clorgyline-induced reduction in [3H]-serotonin binding. Repeated treatment of rats with nialamide also lowered [3H]-serotonin binding and the return of binding sites to control values was correlated temporally with the return of the serotonin concentration to control values. Repeated administration to rats of the serotonin agonists, quipazine or TFMPP, produced a decrease in [3H]-serotonin binding. Both the clorgyline and serotonin agonist-induced reduction in [3H]-serotonin binding were due to a significant reduction in the maximum specific binding capacity with no change in the apparent binding constant. The data presented here are consistent with the hypothesis that MAO inhibitors reduce [3H]-serotonin binding indirectly, by increasing over time the exposure of serotonin receptors to the indolealkylamine.

Original languageEnglish (US)
Pages (from-to)1063-1070
Number of pages8
JournalNeuropharmacology
Volume19
Issue number11
DOIs
StatePublished - 1980
Externally publishedYes

Keywords

  • [H]-serotonin binding
  • monoamine oxidase inhibitors
  • serotonin agonists

ASJC Scopus subject areas

  • Pharmacology
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Decrease in [<sup>3</sup>H]-serotonin binding in rat brain produced by the repeated administration of either monoamine oxidase inhibitors or centrally acting serotonin agonists'. Together they form a unique fingerprint.

Cite this